Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

Dongkyoo Park1, Andrew T. Magis4, Rui Li1, Taofeek K. Owonikoko2, Gabriel L. Sica3, Shi-Yong Sun2, Suresh S. Ramalingam2, Fadlo R. Khuri2, Walter J. Curran1, and Xingming Deng1

Abstract

Bcl-XL is a major antiapoptotic protein in the Bcl-2 family whose overexpression is more widely observed in human lung cancer cells than that of Bcl-2, suggesting that Bcl-XL is more biologically relevant and therefore a better therapeutic target for lung cancer. Here, we screened small molecules that selectively target the BH3 domain (aa 90–98) binding pocket of Bcl-XL using the UCSF DOCK 6.1 program suite and the NCI chemical library database. We identified two new Bcl-XL inhibitors (BXI-61 and BXI-72) that exhibit selective toxicity against lung cancer cells compared with normal human bronchial epithelial cells. Fluorescence polarization assay reveals that BXI-61 and BXI-72 preferentially bind to Bcl-XL protein but not Bcl2, Bcl-w, Bfl-1/A1, or Mcl-1 in vitro with high binding affinities. Treatment of cells with BXI-72 results in disruption of Bcl-XL/Bak or Bcl-XL/Bax interaction, oligomerization of Bak, and cytochrome c release from mitochondria. Importantly, BXI-61 and BXI-72 exhibit more potent efficacy against human lung cancer than ABT-737 but less degree in platelet reduction in vivo. BXI-72 overcomes acquired radioresistance of lung cancer. On the basis of our findings, the development of BXI(s) as a new class of anticancer agents is warranted and represents a novel strategy for improving lung cancer outcome.

Cancer Res; 73(17); 1–12. ©2013 AACR.

Introduction

Lung cancer is the leading cause of cancer-related death in the United States, accounting for 28% of the total estimated cancer deaths (1). The estimated cancer-related mortality from lung cancer alone has surpassed the combined mortality from prostate (11%), colon (9%), and pancreatic cancer (6%) in male patients with cancer (1). The 2 major categories of lung cancer, non–small cell lung cancer (NSCLC; ~85%), and small cell lung cancer (SCLC; ~15%), both have very dismal overall survival rates of 16% and 6%, respectively. Despite recent therapeutic advances, virtually all patients with advanced NSCLCs eventually develop resistance to currently available cytotoxic and targeted therapy (2–4).

One of the well-known hallmarks of cancer is the dysregulation of programmed cell death (i.e., apoptosis), resulting in evasion of apoptosis (5). Impaired apoptosis is a critical step in tumor development and renders the tumor cells more resistant to conventional cytotoxic therapy. Despite the frequent dysregulation of apoptosis in tumors, nearly all tumors maintain the core apoptotic regulatory machinery: Bcl-2 family proteins, cytochrome c (cyt c), caspases, etc. Among the components of the apoptotic machinery, overexpression of the antiapoptotic Bcl-2 family proteins such as Bcl2, Bcl-XL, and Mcl-1 plays critical roles in mediating resistance to apoptosis induced by chemotherapy or radiotherapy (6). Elevated expression levels of antiapoptotic Bcl2 family proteins have been observed in lung cancers and are associated with chemoresistance and poor prognosis (3, 4). Bcl-XL, an antiapoptotic member of the Bcl2 family, is widely expressed in both SCLC and NSCLC cells (4, 7, 8). Bcl-XL also plays important roles in the crosstalk between autophagy and apoptosis (9). Expression of Bcl-XL is associated with resistance against chemotherapeutic agents (4). Therefore, an attempt to overcome this inherent resistance against apoptosis by inactivating Bcl-XL is a very attractive approach for anticancer therapeutics.

Several small-molecule BH3 mimetic compounds such as ABT-737, ABT-263 (the oral form of ABT-737), AT-101, GX15-070, and TW-37 have been developed and evaluated in clinical trials with limited success (8, 10–21). Although ABT-737 is considered a potent anticancer drug, cancer cells expressing high levels of endogenous Bcl-XL exhibit dramatically less sensitivity to ABT-737 (17, 18, 22). To overcome the limitations of currently available Bcl-2 inhibitors for lung cancer treatment, we have developed 2 additional effective anticancer agents (BXI-61 and BXI-72) that specifically target Bcl-XL for the treatment of lung cancers and, potentially, other cancers with high expression levels of endogenous Bcl-XL. Our findings show the efficacy of BXIs in potently repressing lung cancer
and also overcoming acquired radioresistance of lung cancer cells both in vitro and in vivo.

Materials and Methods

Materials

Small molecules, including NSC354961 (BXI-61) and NSC334072 (BXI-72), were obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI, Bethesda, MD; http://dtp.nci.nih.gov/RequestsCompounds). ABT-737 and antibodies, including PARP, Bax, Mcl-1, cyt c, and actin, were purchased from Santa Cruz. Bcl2 antibody was obtained from Calbiochem. Bel-2 and Bak antibodies were purchased from Epitomics. NanoJuice Transfection Kit was obtained from Novogene. Active caspase-3-specific antibody was purchased from Cell Signaling Technology. Fluorescent Bak BH3 domain peptide (FAM-GQVGRQ-LAlIIGDDINRR) and purified Bcl-XL protein were purchased from NeoBioSci. Purified Bcl2 protein was obtained from ProteinX Lab. Purified recombinant Mcl-1 protein was purchased from GenWay Biotech, Inc. Purified recombinant Bcl-w and Bfl-1/A1 proteins were obtained from R&D systems. Bis (maleimido) hexane (BMH) was purchased from Thermo Scientific. All other reagents used were obtained from commercial sources unless otherwise stated.

Cell lines and cell culture

Normal lung epithelial and lung cancer cell lines were obtained from the American Type Culture Collection. SCLC cell lines DMS53, DMS114, and DMS153 were cultured in Weymouth’s medium supplemented with 5% FBS and 5% bovine serum (BS) as described (23). Normal human bronchial epithelial cell line (BEAS-2B) and A549 were cultured in Dulbecco’s Modified Eagles’ Medium (DMEM)/F-12 medium supplemented with 10% FBS. H69, H292, H358, H157, and H358 cells (1 × 10^6) were serially irradiated with 2 Gy of X-rays to a final dose of 80 Gy using X-RAD 320 (Precision X-ray, Inc.). Culture medium was renewed immediately after each dose of radiation. After growing to approximately 90% confluence, cells were trypsinized and passaged into new culture dishes. Re-irradiation of the newly passaged cells with 2 Gy of X-rays occurred at about 60% confluence and this was repeated 40 times over a period of 5 months, for a total dose of 80 Gy. The parental cells (A549-P, H157-P, and H358-P) were also obtaining by irradiation with 2 Gy of X-rays to a final dose of 80 Gy using X-RAD 320 (Precision X-ray, Inc.). Culture medium was renewed immediately after each dose of radiation. After growing to approximately 90% confluence, cells were trypsinized and passaged into new culture dishes. Re-irradiation of the newly passaged cells with 2 Gy of X-rays occurred at about 60% confluence and this was repeated 40 times over a period of 5 months, for a total dose of 80 Gy. The parental cells (A549-P, H157-P, and H358-P) were trypsinized and passaged under the same conditions without irradiation as described (30).

Sulforhodamine B colorimetric assay

Cells were seeded at a density of 6 × 10^3 to 8 × 10^3 per well in 96-well plates and allowed to grow overnight. Cells were treated with BXI or other agent(s) for 72 hours. The surviving cell fraction was determined using the sulforhodamine B (SRB) assay as described (24).

Fluorescence polarization assay

Fluorescent Bak BH3 domain peptide (FAM-GQVGRQ-LAlIIGDDINRR) and Bcl-XL protein were purchased from NeoBioSci. To measure the binding affinity of BXI to Bcl-XL protein, a competition fluorescence polarization assay was used as previously described (25–27). Fluorescent Bak BH3 domain peptide (3 nmol/L) was incubated with purified, human Bcl-XL protein (6 nmol/L) in the absence or presence of increasing concentrations (i.e., 0.1–500 nmol/L) of BXI (s) in the binding affinity assay buffer [50 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.1% bovine serum albumin (BSA), and 5 mmol/L dithiothreitol (DTT)] in a 96-well assay plate. The plate was mixed on a shaker for 1 minute and incubated at room temperature for an additional 15 minutes. Polarization, defined as millipolarization units (mP), was measured at room temperature with a fluorescence microplate reader at 485/530 nm (Gemini XPS, Molecular Devices). A negative control [dimethyl sulfoxide (DMSO), 3 nmol/L peptide and assay buffer] and a positive control (DMSO, 3 nmol/L peptide, 6 mmol/L Bcl-XL, and assay buffer) were used to determine the range of the assay. The percentage of inhibition was determined by the equation: 1 − (mP value of well − negative control)/range) × 100%. Inhibitory constant (K_i) value was determined by the formula: K_i = [I]_50/[E]_50/K_d + [P]_50/K_d + 1) as described (27). Reported values are the mean ± SD for 3 separate experiments run in duplicate.

Cytochrome c release and Bak oligomerization

Subcellular fractionation for isolation of mitochondria and cytosol was conducted as previously described (28). cyt c was analyzed by Western blotting. Bak oligomerization was analyzed as described (29). Briefly, 10 mmol/L BMH was added to the mitochondrial fraction dissolved in conjunction buffer (PBS, pH 7.2) and 5 mmol/L EDTA was added for crosslinking between sulfhydryl groups of Bak proteins. The reaction mixture was incubated for 1 hour at room temperature. The reaction was stopped by adding quench solution (1 mol/L DTT) for 15 minutes at room temperature. The reaction product was subjected to SDS-PAGE gels and analyzed by Western blotting using a Bak antibody.

Establishment of irradiation-resistant cell lines

We chose A549, H157, and H358 cell lines to establish ionizing radiation–resistant lung cancer cell lines (A549-IRR, H157-IRR, and H358-IRR) as described (30). Briefly, A549, H157, and H358 cells (1 × 10^6) were serially irradiated with 2 Gy of X-rays to a final dose of 80 Gy using X-RAD 320 (Precision X-ray, Inc.). Culture medium was renewed immediately after each dose of radiation. After growing to approximately 90% confluence, cells were trypsinized and passaged into new culture dishes. Re-irradiation of the newly passaged cells with 2 Gy of X-rays occurred at about 60% confluence and this was repeated 40 times over a period of 5 months, for a total dose of 80 Gy. The parental cells (A549-P, H157-P, and H358-P) were trypsinized, counted, and passaged under the same conditions without ionizing radiation as described (30).

Lung cancer xenografts and treatments

Six-week-old female nu/nu nude mice were purchased from Harlan and housed under pathogen-free conditions in microisolator cages. All animal treatments were undertaken in accordance with protocols approved by the Institutional Animal Care and Use Committee at Emory University (Atlanta, GA). 3 × 10^6 H1299 cells in Hanks’ Balanced Salt Solution (HBSS, Gibco) were injected into subcutaneous tissue at the flank region of nude mice. The tumors were allowed to grow to an average volume of about 250 mm^3 before initiation of...
therapy as described (18). Mice were treated with BXI-72 or BXI-61 intraperitoneally (i.p.) as indicated. For radiotherapy, mice with A549 parental (A549-P) or A549 irradiation–resistant (A549-IRR) xenografts were irradiated with 2 Gy every other day for 5 treatments using an X-RAD 320 irradiator (Precision X-ray) to deliver whole-body irradiation to the mice at a rate of 0.8 Gy/min as described (31). During treatment, tumor volume \( V \) was measured by caliper measurements once every 2 days and calculated with the formula: 
\[
V = \frac{(L \times W^2)}{2}
\]
(L is the length and W is the width). Mice were sacrificed by inhaled CO2 at the end of treatment. Harvested tumors were weighed and immediately fixed in formalin for immuno-histochemistry.

Mouse blood analysis

Whole blood (250 μL) was collected in EDTA-coated tubes via cardiac puncture of anesthetized mice for hematology studies. Specimens were analyzed for white blood cells (WBC), red blood cells (RBC), platelets (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) in the Clinical Pathology Laboratory at the University of Georgia (Athens, GA).

Statistical analysis

The statistical significance of differences between groups was analyzed with 2-sided unpaired Student t test or Fisher exact test. Results were considered statistically significant at \( P < 0.05 \). The IC\(_{50}\) values were calculated using SPSS Statistics software 18 (IBM). All data are presented as mean ± SD.

Results

Screening of small-molecule BXIs that target the BH3 domain of Bcl-XL (aa 90–98) and suppress lung cancer cell growth

Our findings and those of others have shown that Bcl-XL is more widely expressed than Bcl2 in SCLC and NSCLC cell lines (Fig. 1A; refs. 4, 7, 8), suggesting that Bcl-XL may be a more biologically relevant therapeutic target for lung cancer. To screen for small molecules that specifically target Bcl-XL, a library containing approximately 300,000 small molecules from the NCI was used to dock the structural pocket of the BH3 domain (aa90–98; accession number: 1LXL and 1MAZ) using the UCSF DOCK 6.1 program suite as described (32). The small molecules were ranked according to their energy scores. The top 200 small molecules were selected for screening of cytotoxicity in human lung cancer cells (i.e., H1299 or A549 cells) by SRB assay. Among these small molecules, 2 compounds (i.e., NSC354961 and NSC334072) had the most potent activities against human lung cancer cells. We named these 2 lead compounds Bcl-XL inhibitor BXI-61 (C\(_{20}\)H\(_{19}\)ClN\(_7\)O, MW: 408.86) and BXI-72 (C\(_{27}\)H\(_{29}\)ClN\(_6\)O, MW: 489.01). In this report, we focus on characterizing BXI-61 and BXI-72. The molecular modeling of these 2 leads in complex with Bcl-XL is shown in Fig. 1B. To compare sensitivities of BXIs with ABT-737 in human lung cancer cells, A549, H157, and H1299 cells were treated with increasing concentrations (0, 0.5, 1, 2, 5, 10, 30 μmol/L) of BXI-61, BXI-72, or ABT-737 for 72 hours. The surviving cell fraction was determined using SRB assay. SRB assay estimates cell density based on the

Figure 1. BXIs potently suppress human lung cancer cell growth. A, expression levels of Bcl-XL, Bcl2, Bak, and Bak in various lung cancer cell lines were analyzed by Western blotting. B, structural modeling of BXI-61 and BXI-72 in the BH3 domain binding pocket of Bcl-XL protein. C, A549, H157, and H1299 cells were treated with increasing concentrations of BXI-61, BXI-72, or ABT-737 for 72 hours. Cell growth was analyzed by SRB assay. Error bars represent ± SD.
amount of cellular protein content and is an established and optimized assay for the toxicity screening of compounds on adherent cells in a 96-well format. Results indicate that BXI-61 and BXI-72 are superior to ABT-737 in suppressing lung cancer adherent cells in a 96-well format. Results indicate that BXI-61 and BXI-72 have very low binding affinity (BXI-61: $K_i = 0.08 \pm 0.01 \text{ nmol/L}$; BXI-72: $K_i = 0.15 \text{ nmol/L}$) of BXI-61 or BXI-72 in the presence of increasing protein (6 nmol/L) in the absence or presence of increasing concentrations (i.e., 0.1 to 500 nmol/L) of BXI-61 or BXI-72 in the binding affinity assay buffer. Binding affinities were analyzed using a competition fluorescence polarization assay. Reported values are the mean ± SD for 3 separate experiments run in duplicate.

### Table 1. IC$_{50}$ values of BXI-61, BXI-72, and ABT-737

<table>
<thead>
<tr>
<th>Compound</th>
<th>BXI-61</th>
<th>BXI-72</th>
<th>ABT-737</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549</td>
<td>3.17 ± 0.28</td>
<td>0.68 ± 0.08</td>
<td>19.40 ± 1.23</td>
</tr>
<tr>
<td>H157</td>
<td>5.71 ± 0.49</td>
<td>1.87 ± 0.16</td>
<td>27.55 ± 1.49</td>
</tr>
<tr>
<td>H1299</td>
<td>1.79 ± 0.12</td>
<td>0.49 ± 0.12</td>
<td>40.48 ± 3.56</td>
</tr>
</tbody>
</table>

Bcl2, Mcl-1, Bcl-w, and Bfl-1/A1, indicating the specificity of their binding to Bcl-XL (Fig. 2). Similar ABT-737 binding affinities were observed for Bcl2 and Bcl-XL (Fig. 2). In contrast, BXI-61 and BXI-72 bind significantly tighter to Bcl-XL than Bcl2. This suggests that BXI-61 and BXI-72 specifically target Bcl-XL.

**Bcl-XL is a required target for BXI suppression of human lung cancer growth**

To further test whether Bcl-XL is an essential target for BXI suppression of human lung cancer, endogenous Bcl-XL was knocked down by RNA interference using Bcl-XL short hairpin RNA (shRNA) in H1299 cells (Supplementary Fig. S2A). Approximately 50% to 60% of cells died following transfection with Bcl-XL shRNA at 48 hours. The surviving cells that remained were selected by puromycin for stable clones. The selected stable clones were then identified by Western blotting and treated with BXI compounds. As expected, the effect of Bcl-XL shRNA on Bcl-XL expression was highly specific, as shown by the control shRNA having no effect (Supplementary Fig. S2A). Colony formation assay revealed that depletion of endogenous Bcl-XL significantly reduced the sensitivity of H1299 cells to BXI-61 and BXI-72 (Supplementary Fig. S2B). These findings indicate that Bcl-XL may be a selective target for the effect of BXI on growth inhibition.

**Treatment of human lung cancer cells with BXI results in disruption of Bcl-XL/Bak or Bcl-XL/Bax association, Bak oligomerization, and cyt c release**

Bcl-XL forms a heterodimer with Bak through the BH3 domain and suppresses apoptosis (35, 36). As BXIs are
predicted to target the BH3-binding pocket of Bcl-XL. BXIs may disrupt the Bcl-XL/Bak heterodimerization leading to dissociation of Bak from the Bcl-XL/Bak complex and subsequent Bak homo-oligomerization and activation. To test this hypothesis, H1299 cells expressing high levels of endogenous Bcl-XL and Bak were treated with increasing concentrations of BXI-72 (i.e., 0.1–5 μmol/L) for 24 hours. Co-immunoprecipitation experiments were carried out using a Bcl-XL antibody. Bcl-XL-associated Bak and Bcl-XL were analyzed by Western blotting. Normal IgG was used as control for coimmunoprecipitation. B and C. H1299 cells were treated as in A. Bak oligomerization and cyt c release were analyzed as described in Materials and Methods. Prohibitin was used as a mitochondrial marker.

BXI potently represses lung cancer in animal models

To define the appropriate doses for in vivo experimentation, we first determined the maximum tolerated dose (MTD) as previously described (11). Mice were treated in groups of 6 per dose level with increasing doses of BXI-72 (10–50 mg/kg/d) intraperitoneally for up to 25 days. The 50 mg/kg/d dose was uniformly lethal in the 6 mice within 10 days, whereas 65% of mice treated at the 40 mg/kg/d dose died within 25 days. The dose range between 10 and 30 mg/kg/d was tolerable with no death recorded after 25 days of daily administration (Fig. 4A). We therefore determined the MTD of BXI-72 (i.p.) with 25-day treatment to be approximately 30 to 40 mg/kg/d.

To test whether BXI is active in vivo, we tested the anti-lung cancer efficacy of BXI-72 in lung tumor xenografts as described (18). Results indicate that treatment with BXI-72 resulted in a dose-dependent regression of established lung cancer xenografts (Fig. 4B). To assess whether BXI-72 inhibited tumor growth regression via apoptosis in vivo, representative samples from harvested tumor tissues were analyzed by immunohistochemistry (IHC) for active caspase-3 as described (18). A dose-dependent apoptosis was observed in tumor tissues after BXI-72 treatment (Fig. 4C). Importantly, doses of 20 to 30 mg/kg not only potently suppressed tumor growth but also were well-tolerated without weight loss (Figs. 4 and 5A). However, treatment of mice with increased concentrations of BXI-72 resulted in a dose-dependent reduction of platelets. There were no significant increases in ALT, AST, and BUN or decreases in WBCs and RBCs (Fig. 5B). Histopathology of harvested normal tissues (heart, liver, lung, brain, spleen, kidney, intestine, etc.) revealed no evidence of normal tissue toxicities after treatment with doses of 10 to 30 mg/kg/d (Fig. 5C). However, treatment of mice with doses of 40 to 50 mg/kg/d for 2 weeks resulted in increases in ALT, AST and BUN, indicating renal and hepatic toxicities at these higher doses.
Elevated liver function test was associated with hepatocellular necrosis in mice treated with 50 mg of BXI-72 (Fig. 5C). These findings suggest that doses between 20 and 30 mg/kg provide the optimal therapeutic index for BXI-72 for in vivo experimentation involving lung cancer xenografts. In addition, BXI-61 at dose of 40 mg/kg/d also exhibited high potency against lung cancer without significant normal tissue toxicities except for a slight decrease in platelets (Supplementary Fig. S4).

To compare the antitumor efficacy between BXI-72, BXI-61, and ABT-737 in vivo, mice with H1299 lung cancer xenografts were treated with increasing doses (0, 10, 20, and 30 mg/kg/d) by i.p. for 14 days. Each group includes 8 mice. Tumor volume was measured once every 2 days. After 14 days, the mice were sacrificed and the tumors were removed and analyzed. All P values were compared with control group. C, active caspase-3 was analyzed in tumor tissues at the end of experiments by IHC staining and quantified as described in Materials and Methods.

**BXI overcomes acquired IR resistance both in vitro and in vivo**

To determine whether Bcl2 or Bcl-XL contributes to acquired resistance to radiation, we established an A549 cell line with acquired resistance to ionizing radiation (i.e., A549-IRR) as described (30). Increased levels of Bcl-XL and Bcl2 were observed in A549-IRR cells as compared with A549-P cells (Fig. 7A). Similar findings were also observed in other lung cancer cells (i.e. H157-P/H157-IRR and H358-P/H358-IRR; Supplementary Fig. S5). Importantly, parental A549 (A549-P) cells remained sensitive but A549-IRR became insensitive to IR (Fig. 7B and C). These results provide strong evidence that IR-enhanced Bcl-XL contributes to acquired radioresistance. Intriguingly, both A549-P and A549-IRR cells remained sensitive to BXI-61 and BXI-72 (Fig. 7B and C), suggesting that BXIs are able to overcome acquired radioresistance through their...
suppression of Bcl-XL. To further test whether BXI overcomes radioresistance in vivo, NSCLC xenografts derived from A549-P and A549-IRR cell lines were treated with IR (2 Gy × 5) or BXI-72 (20 mg/kg/d × 18) alone or in combination as indicated. We observed that lung cancer xenografts derived from A549-IRR cells were resistant to IR treatment, whereas xenografts derived from A549-P were sensitive to IR treatment (Fig. 7D). Consistent with the in vitro observation, BXI-72 repressed tumors derived from both A549-P and A549-IRR cells, indicating that BXI-72 can overcome acquired radioresistance in vivo.

Other than a slight decrease in WBC or PLT count in IR- or BXI-72–treated mice, there were no significant normal tissue toxicities (Supplementary Fig. S6).

Discussion

Mimicking the BH3 domain to kill cancers is a strategy that is presently being explored in the development of Bcl2 inhibitors as anticancer drugs (40, 41). By binding to the hydrophobic cleft of Bcl2/Bcl-XL, the BH3 mimetics function as competitive inhibitors (18, 40). Three small-molecule Bcl2 inhibitors, including gossypol (AT-101), obatoclax (GX15-070), and ABT-263, are in clinical trials (phase I/II; refs. 40, 41). Gossypol and obatoclax are BH3 mimetics that act as pan-Bcl2 inhibitors (12, 41). However, gossypol and obatoclax are not entirely dependent on Bax and Bak for apoptosis induction and toxicity to normal cells (40, 42). In contrast, the Bad BH3 mimic ABT-737 was ineffective in inducing apoptosis in cells.
The mechanism of action of ABT-737 appears to be predominantly through the Bcl2 family, as it selectively binds to Bcl2, Bcl-XL, and Bcl-W but not Mcl-1 and Bfl-1/A1. However, ABT-737 resistance can be caused by expression of Mcl-1 and Bcl-XL. Here, we chose the BH3 domain of Bcl-XL (aa 90–98) as a docking site for screening of small molecules that may inactivate Bcl-XL using the UCSF DOCK program 6.1 and a database of small molecules from the NCI. We found 2 new Bcl-XL inhibitors (BXI-61 and BXI-72) that preferentially bind to Bcl-XL with inhibitory constant ($K_i$) values at nanomolar levels, indicating a more selective binding to Bcl-XL. This is especially important because Bcl-XL is more widely expressed in NSCLC and SCLC cells than Bcl-2. A relatively high dose of ABT-737 (i.e., Bcl-2 inhibitor) is required to effectively inhibit the growth of lung cancer cells expressing low levels of endogenous Bcl-2 and high levels of endogenous Bcl-XL. In contrast, our new Bcl-XL inhibitors (i.e., BXI-61 and BXI-72) showed superior efficacy to ABT-737 against lung cancer cells that express high levels of endogenous Bcl-XL. Consistent with our discovery approach, BXI repression of lung cancer growth occurs in a Bcl-XL–dependent manner as depletion of Bcl-XL significantly reduces sensitivity of lung cancer cells to BXI (Supplementary Fig. S2). Importantly, BXI-
Figure 7. BXI-72 overcomes radioresistance of lung cancer in vivo. A, expression levels of Bcl-XL, Bcl-2, Mcl-1, Bak, and Bax in A549-P and A549-IRR cells were analyzed by Western blotting. B and C, A549-P and A549-IRR cells were treated with IR, BXI-61, or BXI-72 as indicated. Cell growth was analyzed by colony formation assay after 10 days (B) or SRB assay after 72 hours (C). D, mice bearing A549-P and A549-IRR lung cancer xenografts were treated with IR, BXI-61, or BXI-72 as indicated. Cell growth was analyzed by colony formation. B, C, and D, each group includes 8 mice. Tumor volume was measured once every 2 days. After 14 days, the mice were sacrificed and the tumors were removed and analyzed. All P values were compared with control group. NS, nonsignificant.

72, which showed a stronger Bcl-XL binding affinity (K<sub>i</sub> = 0.9 ± 0.15 nmol/L), also displayed greater cytotoxicity against human lung cancer cells than BXI-61 (K<sub>i</sub> = 14.8 ± 1.54 nmol/L; Fig. 1C). This thus suggests that the anticancer potency of this new class of agents may be dependent on their Bcl-XL-binding affinity.

Although silencing of Bcl-XL could cause some H1299 cells undergoing apoptosis due to disruption of Bcl-XL/Bak heterodimerization, certain populations of cells may still be alive via a compensatory mechanism (i.e., formation of Bak/Mcl-1 complex) during long-term stable selection because H1299 cells also express high levels of endogenous Mcl-1 protein (46). Thus, there are no or less Bcl-XL molecules in such type of survived cells for BXI targeting. This not only helps explain why the stable Bcl-XL silenced and survived cells were insensitive to BXI treatment (Supplementary Fig. S2) but also suggests that Bcl-XL is a selective target for BXI in cells.

A distinctive feature of Bcl-2 family proteins is that they interact with one another to form heterodimers or homodimers through the Bcl-2 homology (BH) domains (35). Anti-apoptotic Bcl-XL preferentially interacts with Bak and forms a heterodimer that inhibits the pro-apoptotic function of Bak (35). Bak is thought to drive apoptosis by forming homooligomers that permeabilize mitochondria (29). This homooligomerization of Bak is essential for activation of its pro-apoptotic function. Oligomerization involves insertion of the BH3 domain of one Bak molecule into the groove of another (29), and may produce symmetrical Bak dimers. Our results reveal that treatment of lung cancer cells with BXI-72 resulted not only in dissociation of Bak/Bcl-XL or Bax/Bcl-XL complexes but also in Bak oligomerization and cyt c release (Fig. 3), suggesting that the binding of BXI with Bcl-XL could disrupt Bcl-XL/Bak heterodimers and subsequently facilitate Bak activation via its homo-oligomerization. This may be a key

www.aacrjournals.org Cancer Res; 73(17) September 1, 2013 OF9

Published OnlineFirst July 3, 2013; DOI: 10.1158/0008-5472.CAN-12-2272

Downloaded from cancerres.aacrjournals.org on April 11, 2017. © 2013 American Association for Cancer Research.
mechanism by which BXI activates apoptosis leading to cell death and tumor regression \textit{in vitro} and \textit{in vivo}, respectively.

The antitumor activity of BXI \textit{in vivo} was evaluated in lung cancer xenografts. Both BXI-61 and BXI-72 potently repressed lung cancer in animal models (Fig. 4 and Supplementary Fig. S4). We determined the MTD of BXI-72 with a 25-day treatment to be between 30 and 40 mg/kg/d (Fig. 4A). Dose–response experiments indicated that doses of BXI-72 between 20 and 30 mg/kg/d potently repress lung cancer \textit{in vivo} with a slight decrease in platelet count but no other normal tissue toxicity (Figs. 4 and 5), indicating that these doses should be effective and safe for further characterization of this compound in murine lung cancer models. As a dose-dependent increase of apoptosis in tumor tissues was observed in the BXI treatment group, this suggests that repression of lung cancer by BXI occurs through induction of apoptosis in tumors (Fig. 4C).

Recent reports indicate that, in addition to antitumor activity, ABT-737 and ABT-263 can induce thrombocytopenia (47–49). Our findings here show that 2 BXI compounds have more potent efficacy than ABT-737 against lung cancer but less effect on platelet reduction \textit{in vivo} (Fig. 6). It is known that ABT-737 or ABT-263 not only inhibits Bcl-XL but also inhibits Bcl2 and Bcl-w (18), suggesting that ABT-737 or ABT-263 is not a specific Bcl-XL inhibitor, which is a pan-inhibitor for Bcl2, Bcl-XL, and Bcl-w. This could render ABT-737 or ABT-263 more toxicity to normal cells such as platelets. In contrast, BXI-61 or BXI-72 only specifically binds Bcl-XL but not Bcl2, Bcl-w, Mcl-1, and Bfl-1A1 (Fig. 2), indicating that BXI but not ABT-737 is more specific Bcl-XL inhibitor. Thus, BXI may have better chance to let platelet survival because Bcl2 and Bcl-w could be functional after BXI treatment in platelets. This may help explain why BXIs have less effect on platelet reduction than ABT-737 or ABT-263. Because thrombocytopenia is a major problem in cancer therapy, BXI compounds may have advantage and be more valuable in clinic use as compared with ABT-737 or ABT-263.

Radiotherapy is a major therapeutic intervention for patients with lung cancer and is administered to up to 75% of patients with lung cancer during the course of their disease (50). A major challenge affecting outcomes of patients with lung cancer is the development of acquired radioresistance. To test whether BXI could overcome radioresistance of lung cancer, we established acquired radiation-resistant lung cancer cell model systems (Fig. 7 and Supplementary Fig. S5). Elevated levels of the antiapoptotic proteins Bcl-XL and Bcl2 but not Mcl-I were observed in ionizing radiation resistant cells (i.e., A549-IRR vs. A549-P, H157-IRR vs. H157-P, H358-IRR vs. H358-P; Figs. 7A and S5), suggesting that this upregulation could, at least in part, contribute to radioresistance. Intriguingly, the BXI lead compound not only reversed radiation resistance \textit{in vitro} but also overcame radiation resistance \textit{in vivo} at a relatively low dose (i.e., 20 mg/kg/d), leading to the effective suppression of lung cancer xenografts that were resistant to radiation (Fig. 7). Mice tolerated the combination treatment with BXI and IR well without significant normal tissue toxicities except for a reversible decrease in white blood cells that resulted from radiotherapy or a tolerated decrease in platelets that resulted from BXI (Supplementary Fig. S6).

In summary, we have discovered new Bcl-XL inhibitors (BXI-61 and BXI-72) that specifically bind the BH3 domain pocket of Bcl-XL, disrupt Bcl-XL/Bak or Bcl-XL/Bax heterodimerization, and facilitate Bak homo-oligomerization leading to Bak activation and apoptosis in lung cancer cells. These lead compounds have potent activities against lung cancer \textit{in vitro} and \textit{in vivo} and potentially offer superior efficacy over the BH3 mimetic ABT-737 or ABT-263 in lung cancer therapy. The increased levels of Bcl-XL in lung cancer cells with acquired radioresistance make Bcl-XL an ideal target for overcoming radioresistance. As our findings show that BXI can overcome acquired radioresistance of lung cancer \textit{in vitro} and \textit{in vivo}, a combination of BXI with IR may represent an effective new strategy for the treatment of lung cancer, including those patients who are resistant to radiotherapy, leading to long-term tumor-free survival.

Disclosure of Potential Conflicts of Interest

G.L. Sica has a commercial research grant from MorphoTec. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: D. Park, S.S. Ramalingam, W. J. Curran, X. Deng

Development of methodology: D. Park, R. Li, X. Deng

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D. Park, A.T. Magis, S.-Y. Sun, F.R. Khuri, X. Deng


Writing, review, and/or revision of the manuscript: D. Park, A.T. Magis, T.K. Owonikoko, G.L. Sica, S.-Y. Sun, X. Deng

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Li, T.K. Owonikoko, W. J. Curran, X. Deng

Study supervision: F.R. Khuri, X. Deng

Acknowledgments

The authors thank Anthea Hammond for editing of the manuscript.

Grant Support

This work was supported by NCI, NIH grants B01CA112183, B01CA136534, Flight Attendant Medical Research Institute Clinical Innovator Awards, and by NASA grant NNX12AC30G.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 12, 2012; revised June 6, 2013; accepted June 7, 2013; published OnlineFirst July 3, 2013.

References

4. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Forance AJ Jr. An informatics approach identifying markers of


Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

Dongkyoo Park, Andrew T. Magis, Rui Li, et al.

Cancer Res  Published OnlineFirst July 3, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-2272

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/07/09/0008-5472.CAN-12-2272.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.